JP2017530143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530143A5 JP2017530143A5 JP2017517262A JP2017517262A JP2017530143A5 JP 2017530143 A5 JP2017530143 A5 JP 2017530143A5 JP 2017517262 A JP2017517262 A JP 2017517262A JP 2017517262 A JP2017517262 A JP 2017517262A JP 2017530143 A5 JP2017530143 A5 JP 2017530143A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- cancer
- pharmaceutically acceptable
- dispersible
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003826 tablet Substances 0.000 claims description 49
- 239000007919 dispersible tablet Substances 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 22
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 21
- 239000000654 additive Substances 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims description 14
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 210000000481 breast Anatomy 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000001506 calcium phosphate Substances 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 11
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 11
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 11
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 11
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 230000000996 additive effect Effects 0.000 claims description 9
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 9
- 239000004376 Sucralose Substances 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- -1 2,2,2-trifluoro-1,1-dimethyl-ethyl Chemical group 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 206010048832 Colon adenoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000012609 Cowden disease Diseases 0.000 claims description 5
- 201000002847 Cowden syndrome Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 210000001015 abdomen Anatomy 0.000 claims description 5
- 208000009621 actinic keratosis Diseases 0.000 claims description 5
- 210000004100 adrenal gland Anatomy 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000002758 colorectal adenoma Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000000244 kidney pelvis Anatomy 0.000 claims description 5
- 210000000867 larynx Anatomy 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 5
- 208000025113 myeloid leukemia Diseases 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 210000003800 pharynx Anatomy 0.000 claims description 5
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000002314 small intestine cancer Diseases 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 210000000621 bronchi Anatomy 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000006068 taste-masking agent Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 201000010700 sporadic breast cancer Diseases 0.000 description 3
- 208000023516 stroke disease Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059331P | 2014-10-03 | 2014-10-03 | |
| US62/059,331 | 2014-10-03 | ||
| PCT/IB2015/057523 WO2016051374A1 (en) | 2014-10-03 | 2015-10-01 | Pharmaceutical compositions comprising alpelisib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530143A JP2017530143A (ja) | 2017-10-12 |
| JP2017530143A5 true JP2017530143A5 (enExample) | 2018-11-08 |
| JP6723229B2 JP6723229B2 (ja) | 2020-07-15 |
Family
ID=54292871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517262A Active JP6723229B2 (ja) | 2014-10-03 | 2015-10-01 | アルペリシブを含む医薬組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170296523A1 (enExample) |
| EP (2) | EP3200772B1 (enExample) |
| JP (1) | JP6723229B2 (enExample) |
| KR (2) | KR102598782B1 (enExample) |
| CN (2) | CN112957334B (enExample) |
| AU (1) | AU2015326392B2 (enExample) |
| BR (1) | BR112017004694A2 (enExample) |
| CA (1) | CA2962714C (enExample) |
| ES (1) | ES2929554T3 (enExample) |
| MX (1) | MX2017004359A (enExample) |
| PL (1) | PL3200772T3 (enExample) |
| PT (1) | PT3200772T (enExample) |
| RU (1) | RU2690685C2 (enExample) |
| WO (1) | WO2016051374A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919957A (zh) * | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司分散片及其制备方法 |
| AR116299A1 (es) | 2018-09-07 | 2021-04-21 | Sanofi Sa | Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| US20240156752A1 (en) * | 2021-03-11 | 2024-05-16 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2011080502A2 (en) * | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| PH12013502077A1 (en) * | 2011-04-25 | 2013-12-16 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| WO2012170488A1 (en) * | 2011-06-07 | 2012-12-13 | Zx Pharma, Llc | Multiparticulate s-adenosylmethionine compositions and related methods |
| CA2839621A1 (en) * | 2011-06-21 | 2012-12-27 | Novartis Ag | Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
| BR112014023530A2 (pt) * | 2012-03-29 | 2017-07-18 | Novartis Ag | diagnóstico farmacêutico |
| US9827200B2 (en) * | 2012-04-24 | 2017-11-28 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet and production process therefor |
| WO2014007780A1 (en) * | 2012-07-06 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of dexketoprofen |
| EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
-
2015
- 2015-10-01 CN CN202110187770.1A patent/CN112957334B/zh active Active
- 2015-10-01 AU AU2015326392A patent/AU2015326392B2/en active Active
- 2015-10-01 BR BR112017004694A patent/BR112017004694A2/pt not_active Application Discontinuation
- 2015-10-01 ES ES15778761T patent/ES2929554T3/es active Active
- 2015-10-01 RU RU2017114195A patent/RU2690685C2/ru active
- 2015-10-01 PL PL15778761.5T patent/PL3200772T3/pl unknown
- 2015-10-01 MX MX2017004359A patent/MX2017004359A/es unknown
- 2015-10-01 KR KR1020237000178A patent/KR102598782B1/ko active Active
- 2015-10-01 EP EP15778761.5A patent/EP3200772B1/en active Active
- 2015-10-01 WO PCT/IB2015/057523 patent/WO2016051374A1/en not_active Ceased
- 2015-10-01 US US15/515,621 patent/US20170296523A1/en not_active Abandoned
- 2015-10-01 PT PT157787615T patent/PT3200772T/pt unknown
- 2015-10-01 JP JP2017517262A patent/JP6723229B2/ja active Active
- 2015-10-01 CN CN201580054000.2A patent/CN107106497A/zh active Pending
- 2015-10-01 CA CA2962714A patent/CA2962714C/en active Active
- 2015-10-01 EP EP22187029.8A patent/EP4169508A1/en active Pending
- 2015-10-01 KR KR1020177008575A patent/KR102486126B1/ko active Active
-
2019
- 2019-04-15 US US16/363,004 patent/US20190314353A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/853,537 patent/US20220331305A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160014T1 (hr) | Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti | |
| KR102490547B1 (ko) | 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물 | |
| JP2017537126A (ja) | 非小細胞肺癌に対するキノリン誘導体 | |
| JP2017530143A5 (enExample) | ||
| JP7374885B2 (ja) | 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤 | |
| JP6220485B2 (ja) | コロイドビスマスペクチンを含有する分散製剤及びその製造方法 | |
| TW201919632A (zh) | 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物 | |
| CN112057451A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| KR20210117300A (ko) | 포스포디에스테라제 억제제를 함유하는 변형 방출 정제 제형 | |
| CN102198110A (zh) | 富马酸替诺福韦二吡呋酯分散片及其制备方法 | |
| JP6855488B2 (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| CN104755463A (zh) | 非晶态形式的喹啉衍生物及其生产方法 | |
| JP2022521683A (ja) | 過剰増殖性疾患の治療における使用のためのａｔｒキナーゼ阻害剤ｂａｙ１８９５３４４ | |
| RU2017114195A (ru) | Фармацевтические композиции, содержащие алпелисиб | |
| CN105476967A (zh) | 一种布南色林药物组合物及其制备方法 | |
| CN115279347A (zh) | Ahr抑制剂和其用途 | |
| CN102488681A (zh) | 布洛芬苯海拉明口腔崩解片及其制备方法 | |
| JP2015533165A (ja) | 組み合わせ | |
| KR101601794B1 (ko) | 클로미프라민 함유 맛 차폐된 구강 투여용 약학 제제 | |
| CN103585125B (zh) | 一种甲磺酸卡莫司他口崩片及其制备方法和其新应用 | |
| KR102744499B1 (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| CN115666516A (zh) | 包括卡培他滨的快速分散药物组合物 | |
| CN102846571A (zh) | 一种埃索美拉唑镁微型片剂 | |
| JP2016098190A (ja) | テルミサルタンを含む経口医薬組成物 | |
| CN103349652A (zh) | 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂 |